Both trials tested a selective oral SGLT2 inhibitor in their analysis of patients with or without diabetes, heart failure, and an LVEF of more than 40%, with similar inclusion and exclusion criteria and a similar primary composite outcome. Here, SLC5A2 is linked to heart failure.